Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 12Brain Neoplasms 6Breast Neoplasms, Male 5Glioblastoma 4Gliosarcoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Oligodendroglioma 2Glioma 2Gallbladder Neoplasms 2Ependymoma 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Astrocytoma 2Tongue Neoplasms 1Thyroid Neoplasms 1Thymoma 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Neoplasms 1Melanoma 1Medulloblastoma 1Insulin-Like Growth Factor I, Resistance To 1Familial ependymoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 9Specimen Handling 4Iodine-131 4Trastuzumab 3Thyrotropin Alfa 3Sorafenib 3Nivolumab 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3trametinib 2tipifarnib 2romidepsin 2omipalisib 2dabrafenib 2cabozantinib 2aldesleukin 2Triiodothyronine 2Sunitinib 2Ipilimumab 2Iodine-124 2CTLA-4 Antigen 2Bortezomib 2Biopsy 2vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1tanespimycin 1sargramostim 1sapanisertib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thyroid Neoplasms × Lapatinib × Clear all
NCT01947023 2026-05-14

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
23 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡